Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers

Document Type: Original Article

Authors

1 Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran

2 Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran 2 Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran

3 Internal Medicine Dept, Amir al Moemenin Hospital, Arak University of Medical Sciences.

4 Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran

5 Navid Medical Lab, Mashhad- Iran

Keywords


Gallo RC. History of the discoveries of the first human retroviruses:
HTLV-I and HTLV-II. Oncogene 2005; 24:5926-30. Epub
2005/09/13.
2. Yamashiro T, Kamiya H, Miyara T, Gibo S, Ogawa K, Akamine T,
 
et
al.
 
 
 
CT scans of the chest in carriers of human T-cell lymphotropic
virus type 1: presence of interstitial pneumonia. Acad Radiol
 
2012; 19:952-957. Epub 2012/05/15.
 
3. Naderi M, Paryan M, Azadmanesh K, Rafatpanah H, Rezvan H,
 
Mirab Samiee S. Design and development of a quantitative
 
real time PCR assay for monitoring of HTLV-I provirus in whole
 
blood. Journal of clinical virology : the official publication of the
 
Pan American Society for Clinical Virology. 2012; 53:302-307. Epub
 
2012/02/07.
 
4. Trevino A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM,
 
 
 
et al.
 
Trends in the prevalence and distribution of HTLV-I and HTLV-II
infections in Spain. Virol J 2012; 9:71. Epub 2012/03/27.
5. Sadeghian MH, Keramati MR, Ayatollahi H, Feizabadi AS, Tehranaian
F, Shakibyee H. Is there any relationship between expressions
of minor blood group antigens with HTLV-I infection?
Transfusion and apheresis science : official journal of the World
Apheresis Association : official journal of the European Society
for Haemapheresis. Transfus Apher Sci 2012; 47:151-154. Epub
2012/08/04.
6. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,
Bidkhori HR, Shamsian SK, Ahmadi S,
et al.
High prevalence of
HTLV-I infection in Mashhad, Northeast Iran: a population-based
 
seroepidemiology survey. Journal of clinical virology : the official
 
publication of the Pan American Society for Clinical Virology.
 
J Clin Virol 2011; 52:172-176. Epub 2011/08/16.
 
7. Azarpazhooh MR HK, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-
 
Moghaddam MR, Valizadeh N
 
 
, et al
. Human T-lymphotropic
virus type 1 prevalence in northeastern Iran, Sabzevar: an
 
epidemiologic-based study and phylogenetic analysis. AIDS Res
 
Hum Retroviruses 2012; 28:1095-10101.
 
8. Saito M. Immunogenetics and the Pathological Mechanisms
 
of Human T-Cell Leukemia VirusType 1- (HTLV-I-)Associated Myelopathy/
 
Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect
 
Infect Dis 2010; 2010:478461. Epub 2010/02/20.
 
9. Abdelbary NH, Abdullah HM, Matsuzaki T, Hayashi D, Tanaka
 
Y, Takashima H,
 
 
et al.
Reduced Tim-3 expression on human Tlymphotropic
virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes
 
in HTLV-I infection. J Infect Dis 2011; 203:948-959. Epub
 
2011/03/16.
 
10. Cabrera ME, Labra S, Catovsky D, Ford AM, Colman SM, Greaves
 
MF,
 
 
et al.
HTLV-I positive adult T-cell leukaemia/lymphoma (ATLL)
in Chile. Leukemia 1994; 8:1763-1767. Epub 1994/10.01/
 
11. Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S,
 
 
et al
. Phase II study on combination therapy with CHOP-Zenapax
for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
 
Leukemia Res 2012; 36:857-861. Epub 2012/01/03.
 
12. Kokoris SI, Siakantaris MP, Kontopidou FN, Kyrtsonis MC, Tsakris
 
A, Spanakis N,
 
 
et al.
Adult T-cell leukemia/lymphoma (ATLL): report
of two fully documented Hellenic patients. Leukemia Lymphoma
 
2004; 45:715-21. Epub 2004/05/27.
 
13. Costa DT, Sundberg M, Passos L, Muniz AL, Santos S. Interferon
 
Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and
 
Modifies the Immune Response in a Patient with HAM/TSP. Case
 
Rep Neurol Med 2012; 2012:958786. Epub 2012/09/07.
 
14. Cabral F ,Arruda LB, de Araujo ML, Montanheiro P, Smid J, de
 
Oliveira AC,
 
 
et al.
Detection of human T-cell lymphotropic virus
type 1 in plasma samples. Virus Res 2012; 163:87-90. Epub
 
2011/09/20.
 
15. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr
 
L,
 
 
et al.
The impact of interferon-alpha treatment on clinical
and immunovirological aspects of HTLV-I-associated myelopathy
 
in northeast of Iran. J Neuroimmunol 2012; 250:87-93. Epub
 
2012/06/26.
 
16. Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R,
 
 
et al
. HTLV tax: a fascinating multifunctional co-regulator of
viral and cellular pathways. Front Microbiol 2012; 3:406. Epub
 
2012/12/12.
 
17. Leal FE, Ndhlovu LC, Hasenkrug AM, Bruno FR, Carvalho KI,
 
Wynn-Williams H,
 
 
et al
. Expansion in CD39(+) CD4(+) Immunoregulatory
T Cells and Rarity of Th17 Cells in HTLV-I Infected Patients
 
Is Associated with Neurological Complications. PLoS Negl
 
Trop Dis 2013; 7:e2028. Epub 2013/02/15.
 
18. Yamano Y, Sato T .Clinical pathophysiology of human T-lymphotropic
 
virus-type 1-associated myelopathy/tropical spastic para
 
 
 
219
 
HTLV-I proviral load in ATL, HAM-TSP and healthy carriers Akbarin MM R et al
Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013
paresis. Front Microbiol 2012; 3:389. Epub 2012/11/20.
19. Tsukasaki K, Imaizumi Y, Tawara M, Fujimoto T, Fukushima T,
Hata T,
et al
. Diversity of leukaemic cell morphology in ATL correlates
with prognostic factors, aberrant immunophenotype and
 
defective HTLV-I genotype. Br J Haematol 1999; 105:369-375. Epub
 
1999/05/08.
 
20. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A ,Uchimaru K,
 
Koh KR,
 
 
et al
. Human T-cell leukemia virus type I (HTLV-I) proviral
load and disease progression in asymptomatic HTLV-I carriers: a
 
nationwide prospective study in Japan. Blood 2010; 116:1211-1219.
 
Epub 2010/05/08.
 
21. Taylor GP TJ, Matutes E. Prospective study of HTLV-I infection in
 
an initially asymptomatic cohort. J Acquir Immune Defic Syndr
 
1999; 22:92-100.
 
22. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi
 
M,
 
 
et al.
Phase 2 study of the efficacy and safety of the combination
of arsenic trioxide, interferon alpha, and zidovudine in
 
newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
 
Blood 2009; 113:6528-6532. Epub 2009/05/05.
 
23. Nasr R, El Hajj H, Kfoury Y, de The H, Hermine O, Bazarbachi A.
 
Controversies in targeted therapy of adult T cell leukemia/lymphoma:
 
ON target or OFF target effects? Viruses 2011; 3:750-769.
 
Epub 2011/10/14.
 
24. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematopathol
 
2010 .25-50:9 ;Epub 2010/05/28.
 
25. Nagai M UK, Matsumoto W, Kodama D, Takenouchi N, Moritoyo
 
T. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and
 
243 asymptomatic HTLV-I carriers: high proviral load strongly
 
predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593.
 
26. Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J,
 
 
et al.
SYBR Green-based quantitation of human T-lymphotropic
virus type 1 proviral load in Peruvian patients with neurological
 
disease and asymptomatic carriers: influence of clinical status,
 
sex ,and familial relatedness. J Neurovirol 2006; 12:456-465. Epub
 
2006/12/13.
 
27. Montanheiro P, Olah I, Fukumori LM, Smid J, Oliveira AC, Kanzaki
 
LI,
 
 
et al.
Low DNA HTLV-II proviral load among women in Sao Paulo
City. Virus Res 2008;135:22-25. Epub2008/03/18.